236 related items for PubMed ID: 9205742
1. Effect of ebrotidine on ethanol-induced gastric mucosal damage in the rat. Comparative study with other H2-receptor antagonists.
Palop D, Romero A, Villamayor F, Conejo L, Sacristán A, Ortiz JA.
Arzneimittelforschung; 1997 Apr; 47(4A):450-4. PubMed ID: 9205742
[Abstract] [Full Text] [Related]
2. Histamine H2-receptor antagonist action of ebrotidine. Effects on gastric acid secretion, gastrin levels and NSAID-induced gastrotoxicity in the rat.
Palop D, Agut J, Márquez M, Conejo L, Sacristán A, Ortiz JA.
Arzneimittelforschung; 1997 Apr; 47(4A):439-46. PubMed ID: 9205740
[Abstract] [Full Text] [Related]
3. Involvement of endogenous nitric oxide and sulfhydryl compounds in ebrotidine-induced gastroprotection.
Palop D, Conejo L, Sacristán A, Ortiz JA.
Arzneimittelforschung; 1997 Apr; 47(4A):468-71. PubMed ID: 9205745
[Abstract] [Full Text] [Related]
4. Study on the increment of the amount of gastric mucus in rats after repeated-dose administration of ebrotidine.
Romero A, Villamayor F, Palop D, Falcó J, Sacristán A, Ortiz JA.
Arzneimittelforschung; 1997 Apr; 47(4A):455-8. PubMed ID: 9205743
[Abstract] [Full Text] [Related]
5. Studies on the cytoprotective and antisecretory activity of ebrotidine. A review.
Konturek PC, Brzozowski T, Konturek SI, Márquez M, Torres J, Ortiz JA.
Arzneimittelforschung; 1997 Apr; 47(4A):578-89. PubMed ID: 9205769
[Abstract] [Full Text] [Related]
6. Gastroprotective properties of ebrotidine. A review.
Slomiany BL, Piotrowski J, Slomiany A.
Arzneimittelforschung; 1997 Apr; 47(4A):459-67. PubMed ID: 9205744
[Abstract] [Full Text] [Related]
7. Comparative study of plasma gastrin levels in rats after two months of ebrotidine administration.
Romero A, Gómez F, Villamayor F, Ballesta A, Sacristán A, Ortiz JA.
Arzneimittelforschung; 1997 Apr; 47(4A):524-7. PubMed ID: 9205757
[Abstract] [Full Text] [Related]
8. Anti-Helicobacter pylori activities of ebrotidine. A review of biochemical and animal experimental studies and data.
Slomiany BL, Piotrowski J, Slomiany A.
Arzneimittelforschung; 1997 Apr; 47(4A):475-82. PubMed ID: 9205747
[Abstract] [Full Text] [Related]
9. Studies on the protective effect of ebrotidine on experimental ulcers induced by non-steroidal anti-inflammatory drugs in healthy volunteers.
Puscas I, Puscas C, Coltau M, Torres J, Márquez M, Herrero E, Fillat O, Ortiz JA.
Arzneimittelforschung; 1997 Apr; 47(4A):565-8. PubMed ID: 9205766
[Abstract] [Full Text] [Related]
10. Ebrotidine--a new H2-receptor antagonist with mucosal strengthening activity.
Piotrowski J, Yamaki K, Morita M, Slomiany A, Slomiany BL.
Biochem Int; 1992 Mar; 26(4):659-67. PubMed ID: 1351724
[Abstract] [Full Text] [Related]
11. Action of ebrotidine, ranitidine and cimetidine on the specific binding to histamine H1- and H2-receptors.
Agut J, Sánchez JC, Sacristán A, Ortiz JA.
Arzneimittelforschung; 1997 Apr; 47(4A):447-9. PubMed ID: 9205741
[Abstract] [Full Text] [Related]
12. Comparative study of the safety and efficacy of ebrotidine versus ranitidine and placebo in the prevention of piroxicam-induced gastroduodenal lesions.
Puscas I, Puscas C, Coltau M, Pasca R, Torres J, Márquez M, Herrero E, Fillat O, Ortiz JA.
Arzneimittelforschung; 1997 Apr; 47(4A):568-72. PubMed ID: 9205767
[Abstract] [Full Text] [Related]
13. Study of the population of antral G-cells and enterochromaffin-like cells in the rat and mouse gastric mucosa after long-term treatment with ebrotidine.
Romero A, Gómez F, Villamayor F, Sacristán A, Ortiz JA.
Arzneimittelforschung; 1997 Apr; 47(4A):520-3. PubMed ID: 9205756
[Abstract] [Full Text] [Related]
14. Effect of ebrotidine on gastric mucosal calcium channel activity.
Slomiany BL, Liu J, Kawai T, Czajkowski A, Slomiany A.
Am J Gastroenterol; 1993 Jun; 88(6):881-6. PubMed ID: 8099251
[Abstract] [Full Text] [Related]
15. Regulation of gastric mucosal calcium channel activity by an antiulcer agent, ebrotidine.
Slomiany BL, Liu J, Piotrowski J, Czajkowski A, Yotsumoto F, Slomiany A.
J Physiol Pharmacol; 1994 Mar; 45(1):121-31. PubMed ID: 7519082
[Abstract] [Full Text] [Related]
16. Subacute toxicity of ebrotidine in rats and dogs.
Romero A, Grau MT, Villamayor F, Sacristán A, Ortiz JA.
Arzneimittelforschung; 1997 Apr; 47(4A):492-7. PubMed ID: 9205751
[Abstract] [Full Text] [Related]
17. Gastroprotective and ulcer-healing activities of a new H2-receptor antagonist: ebrotidine.
Brzozowski T, Majka J, Konturek SJ.
Digestion; 1992 Apr; 51(1):27-36. PubMed ID: 1353465
[Abstract] [Full Text] [Related]
18. Continuous intragastric pH monitoring in the evaluation of ebrotidine, cimetidine and placebo on gastric acidity in healthy volunteers.
Muñoz-Navas M, Honorato J, Reina-Ariño M, Márquez M, Herrero E, Villamayor F, Torres J, Roset PN, Fíllat O, Camps F, Ortiz JA.
Arzneimittelforschung; 1997 Apr; 47(4A):539-44. PubMed ID: 9205761
[Abstract] [Full Text] [Related]
19. Gastric acid inhibitory profile of ebrotidine, a novel H2-receptor antagonist in humans.
Maczka M, Kwiecień N, Obtułowicz W, Konturek SJ, Kamiński K, Oleksy J, Gabryelewicz A, Torres J.
J Physiol Pharmacol; 1992 Jun; 43(2):139-48. PubMed ID: 1356519
[Abstract] [Full Text] [Related]
20. Effect of ebrotidine on gastric mucosal EGF and PDGF receptor expression.
Piotrowski J, Czajkowski A, Yotsumoto F, Slomiany A, Slomiany BL.
Biochem Mol Biol Int; 1993 Aug; 30(6):1127-34. PubMed ID: 8106073
[Abstract] [Full Text] [Related]
Page: [Next] [New Search]
